Cevian Capital filed a Schedule 13D amendment in late July disclosing a stake above 14% in Smith & Nephew, the $14.6 billion London-listed medical device manufacturer. The Swedish activist has now accumulated shares for five consecutive quarters, building what is likely its largest single position outside European industrial conglomerates. Smith & Nephew trades at 11.2x forward earnings, a 34% discount to peers Stryker and Zimmer Biomet, despite comparable operating margins in the 18-19% range.
The timing matters. Smith & Nephew announced CEO Deepak Nath's departure in May after eighteen months in the role, naming CFO Anne-Françoise Nesmes as interim chief while the board conducts a search expected to conclude by year-end. The company has missed analyst estimates in four of the past six quarters, with its orthopaedics division growing at 3.1% versus the sector's 5.8% average. Cevian's stake crossed 10% in Q1 2024, then 12% in Q4 2023 filings, each time without board representation or public campaign materials. The latest amendment suggests accumulation continued through June and early July, prior to the CEO transition announcement reaching the market.
Cevian runs $15 billion and specializes in operational overhauls at underperforming European industrials, typically holding 5-10 concentrated positions for three to seven years. Portfolio companies include ThyssenKrupp, where Cevian pushed for steel-division separation, and Pandora, where margins expanded 680 basis points over a four-year engagement. Smith & Nephew's 23% share-price decline since January 2022 reflects concerns over U.S. market-share losses in knee implants and delayed product launches in the advanced wound-care segment, which accounts for 29% of revenue. The company's return on invested capital has fallen from 12.4% in 2019 to 8.9% in the trailing twelve months, below its 10.2% weighted average cost of capital.
Allocators should watch for three catalysts. First, the CEO appointment, expected between October and December, will signal whether the board accepts operational restructuring or opts for continuity. Second, Smith & Nephew's Q3 earnings in late October will show whether the orthopaedics division stabilized after two quarters of sequential deceleration. Third, any Cevian board-seat request would appear in a subsequent 13D amendment, historically filed 60-90 days after the activist crosses 12% in European cross-listings. The firm has not yet issued a public letter or white paper.
Smith & Nephew's enterprise value sits at $16.8 billion with $2.3 billion in net debt, offering a break-up scenario where the sports medicine and advanced wound-care units could trade separately at sector multiples in the 14-16x range. Cevian's average holding period and the CEO search timeline place the next inflection point in Q4 2024.